To evaluate whether Sofosbuvir (SOF)/Velpatasvir (VEL) with or without Ribavirin (RBV) change the landscape of therapy in chronic hepatitis C genotype 3 (GT 3) infection

Trial Profile

To evaluate whether Sofosbuvir (SOF)/Velpatasvir (VEL) with or without Ribavirin (RBV) change the landscape of therapy in chronic hepatitis C genotype 3 (GT 3) infection

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Sofosbuvir/velpatasvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms GECCO
  • Most Recent Events

    • 14 Mar 2018 Results assessing efficacy and saftey of treatment with Sofosbuvir (SOF)/Velpatasvir (VEL) with or without Ribavirin (RBV) for 12 weeks in a real world setting, published in the Alimentary Pharmacology and Therapeutics
    • 24 Oct 2017 Results (n=2280; as of Mar 2017) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 11 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top